Ting Seng Tang1, Thomas Bieber2, Hywel C Williams3. 1. Centre of Evidence Based Dermatology, King's Meadow Campus, University of Nottingham, Nottingham, United Kingdom. Electronic address: kyle.tang@gmail.com. 2. Centre of Evidence Based Dermatology, King's Meadow Campus, University of Nottingham, Nottingham, United Kingdom; Department of Dermatology and Allergy, Friedrich-Wilhelms-Universität, Bonn, Germany. 3. Centre of Evidence Based Dermatology, King's Meadow Campus, University of Nottingham, Nottingham, United Kingdom.
Abstract
BACKGROUND: Atopic dermatitis (AD) treatment is often initiated by symptoms or visible erythema. The role of induction of remission or treatment of inflammation that is not visible is unclear. OBJECTIVE: We investigated whether (1) the notion of subclinical inflammation is scientifically sound, (2) treatment corrects subclinical inflammation, and (3) different strategies for initial clearance of AD affect long-term disease control. METHODS: We conducted a systematic review based on searching MEDLINE, Embase, the Cochrane register of randomized controlled trials, and the Global Resource of Eczema Trials from inception to the end of October 2012. RESULTS: Twenty of 26 included studies presented evidence of subclinical inflammation, with a continuum of changes in skin barrier dysfunction, the proinflammatory cytokine milieu, and lymphocytic infiltration from normal-appearing skin to posttreatment lesional skin to active skin lesions in patients with AD. Such subclinical inflammation is improved, with proactive treatment aimed at maintaining remission. Failure to achieve control of AD symptoms with initial therapy was associated with a higher risk of relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrolimus: risk ratio, 1.36; 95% CI, 1.12-1.66). Three trials on systemic therapy/phototherapy suggested that induction of remission resulted in long-term remission without maintenance therapy in approximately 15% of patients. CONCLUSION: Induction of remission followed by maintenance therapy might prove to be an integral part of a disease-modifying strategy for treating atopic diseases.
BACKGROUND:Atopic dermatitis (AD) treatment is often initiated by symptoms or visible erythema. The role of induction of remission or treatment of inflammation that is not visible is unclear. OBJECTIVE: We investigated whether (1) the notion of subclinical inflammation is scientifically sound, (2) treatment corrects subclinical inflammation, and (3) different strategies for initial clearance of AD affect long-term disease control. METHODS: We conducted a systematic review based on searching MEDLINE, Embase, the Cochrane register of randomized controlled trials, and the Global Resource of Eczema Trials from inception to the end of October 2012. RESULTS: Twenty of 26 included studies presented evidence of subclinical inflammation, with a continuum of changes in skin barrier dysfunction, the proinflammatory cytokine milieu, and lymphocytic infiltration from normal-appearing skin to posttreatment lesional skin to active skin lesions in patients with AD. Such subclinical inflammation is improved, with proactive treatment aimed at maintaining remission. Failure to achieve control of AD symptoms with initial therapy was associated with a higher risk of relapse in 14 randomized controlled trials (fluticasone: risk ratio, 1.31; 95% CI, 1.02-1.68; tacrolimus: risk ratio, 1.36; 95% CI, 1.12-1.66). Three trials on systemic therapy/phototherapy suggested that induction of remission resulted in long-term remission without maintenance therapy in approximately 15% of patients. CONCLUSION: Induction of remission followed by maintenance therapy might prove to be an integral part of a disease-modifying strategy for treating atopic diseases.
Authors: Robert A Byers; Raman Maiti; Simon G Danby; Elaine J Pang; Bethany Mitchell; Matt J Carré; Roger Lewis; Michael J Cork; Stephen J Matcher Journal: Biomed Opt Express Date: 2018-03-29 Impact factor: 3.732
Authors: Marissa T Ayasse; Adnan Ahmed; Maria L Espinosa; Christina J Walker; Muhammad Yousaf; Jacob P Thyssen; Jonathan I Silverberg Journal: Arch Dermatol Res Date: 2020-11-22 Impact factor: 3.017
Authors: Christoph Riethmuller; Maeve A McAleer; Sjors A Koppes; Rawad Abdayem; Jonas Franz; Marek Haftek; Linda E Campbell; Stephanie F MacCallum; W H Irwin McLean; Alan D Irvine; Sanja Kezic Journal: J Allergy Clin Immunol Date: 2015-06-11 Impact factor: 10.793
Authors: Thomas Luger; Mark Boguniewicz; Warner Carr; Michael Cork; Mette Deleuran; Lawrence Eichenfield; Philippe Eigenmann; Regina Fölster-Holst; Carlo Gelmetti; Harald Gollnick; Eckard Hamelmann; Adelaide A Hebert; Antonella Muraro; Arnold P Oranje; Amy S Paller; Carle Paul; Luis Puig; Johannes Ring; Elaine Siegfried; Jonathan M Spergel; Georg Stingl; Alain Taieb; Antonio Torrelo; Thomas Werfel; Ulrich Wahn Journal: Pediatr Allergy Immunol Date: 2015-04-13 Impact factor: 6.377
Authors: Panayiotis Christodoulides; Yoshito Hirata; Elisa Domínguez-Hüttinger; Simon G Danby; Michael J Cork; Hywel C Williams; Kazuyuki Aihara; Reiko J Tanaka Journal: Philos Trans A Math Phys Eng Sci Date: 2017-06-28 Impact factor: 4.226
Authors: Emma Axon; Joanne R Chalmers; Miriam Santer; Matthew J Ridd; Sandra Lawton; Sinead M Langan; Douglas J C Grindlay; Ingrid Muller; Amanda Roberts; Amina Ahmed; Hywel C Williams; Kim S Thomas Journal: BMJ Open Date: 2021-07-07 Impact factor: 2.692